Observational Study of FTT PET/CT in Metastatic Prostate Cancer
This observational study is looking at men with metastatic prostate cancer to see how a special imaging scan, called FTT PET/CT, can measure PARP activity in their cancer. PARP is a protein that helps repair damaged DNA in cancer cells. You would receive an investigational radiopharmaceutical called [18F]FluorThanatrace, which helps the FTT PET/CT scan show PARP activity. Up to 30 men will have at least one FTT PET/CT scan before starting a new treatment, and some may have a second scan after starting treatment. The study aims to see how well the FTT PET/CT scan measures PARP activity in the cancer. The current status of this study is unclear.
- Study design
- This is an observational study involving up to 30 men. It is not specified if it is blinded or what phase it is in.
- What's involved
- You would undergo up to two FTT PET/CT scans. The first scan is before starting new therapy, and the second, optional, scan is 1-21 days after starting treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measurement is taken at 21 days after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
FTT PET/CT in Metastatic Prostate Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Neil Taunk, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Measurement of effect size21 days
To establish effect size of change in FTT uptake before and after systemic therapy in men with prostate cancer metastasis using \[18F\]FluorThanatrace (\[18F\]FTT)